跳至主要内容
临床试验/TCTR20220819001
TCTR20220819001已完成3 期

Quickstarting oral contraceptive on Day 7-9 of menstruation, 4mg Drospirenone VS combined oral contraceptive pill, focusing on ovulation inhibition: A single-blind, randomized controlled, non-inferiority trial.

Thai red cross research committee0 个研究点目标入组 36 人开始时间: 2022年8月19日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 45 Years(—)
性别
Female

入选标准

  • 1. Women aged 18 to 45 years old
  • 2. Body mass index 18 to 30 kg/m2
  • 3. Agree to use a condom as contraception or be sterilized
  • 4. Agree to participate in this study and complete an informed consent form
  • 5. Menstruation interval within 24-38 days

排除标准

  • 1. History of estrogen, progestin or testosterone use within 3 months
  • 2. Being pregnant or within 3 months of breastfeeding
  • 3. Being a cervical cancer patient or having a precancerous cervical lesion
  • 4. History of allergy to estrogen or progestin
  • 5. Ovarian cyst or ovarian tumor
  • 6. Any conditions in US Medical Eligibility Criteria 3 or 4 for progestin-only pills or combined oral contraceptive pills

研究者

发起方
Thai red cross research committee

相似试验